Document:

<PAGE>

                                                                    EXHIBIT 10.3

                                LICENSE AGREEMENT

      THIS LICENSE AGREEMENT ("Agreement") is made and is effective as of August
1, 1996 by and between the UNIVERSITY OF UTAH RESEARCH FOUNDATION, a Utah
non-profit corporation, having its principal place of business at 421 Wakara
Way, Suite 170, Salt Lake City, UT 84108, hereinafter referred to as "Licensor",
and BIONIC TECHNOLOGIES, INC., a corporation, having its principal place of
business at 1763 East 900 South, Salt Lake City, UT 84108, hereinafter referred
to as "Licensee".

                               W I T N E S S E T H

      WHEREAS, certain inventions, generally characterized as * * * and assigned
University of Utah identification number * * * and * * * respectively,
hereinafter collectively referred to as "the Inventions", have been made in the
course of research conducted at the University of Utah by Richard Normann, Kelly
E. Jones and Patrick K. Campbell, Patrick J. Rousche, Kenneth W. Horch and Susan
P. Schmidt are covered by Licensor's Patent Rights and Licensed Technology (as
defined below);

      WHEREAS, Licensor desires that the Inventions be developed and utilized to
the fullest extent so that its benefits can be enjoyed by the general public;

      WHEREAS, Licensee wishes to obtain from Licensor a license under certain
rights for the commercial development, production, manufacture, use and sale of
the Inventions, and Licensor is willing to grant such a license upon the terms
and conditions hereinafter set forth;

      NOW THEREFORE, for and in consideration of the covenants, conditions and
undertakings hereinafter set forth, the parties hereby agree as follows:

                              ARTICLE 1 DEFINITIONS

      Section 1.1 "Licensor's Patent Rights" means patent rights to any subject
matter claimed in or covered by (a) any pending or issued United States or
foreign patent or any patent application listed on Exhibit "A" attached hereto,
which is incorporated herein by this reference;

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

<PAGE>

(b) any continuing or divisional applications thereof; and (c) any patents
issuing on continuing, continuation-in--part or divisional applications,
including reissues thereof.

      Section 1.2 "FIELD OF USE" means the sale and/or use of any Licensed
Product and/or Licensed Service in the performance of research and development
of the inventions on various animal and human subjects, for which sale and/or
use the approval from the Food and Drug Administration is not required or has
not been obtained.

      Section 1.3 "Licensed Technology" means the technology associated with the
inventions and any intellectual property therein, that has been developed by Dr.
Richard Norman and his co-workers at the University of Utah including those
technologies listed in Exhibit "B".

      Section 1.4 "Licensed Product" means any product, apparatus, kit or
component part thereof, or any other subject matter the manufacture, use or sale
of which is covered by any claim or claims included within Licensor's Patent
Rights or which incorporates Licensed Technology.

      Section 1.5 "Licensed services" means any method, procedure, process or
other subject matter, the manufacture, use, or sale of which is covered by any
claim or claims included within Licensor's Patent Rights and/or which
incorporates Licensed Technology.

      Section 1.6 " . . .covered by . . ." means a Licensed Product that, when
made, used or sold, or a Licensed Service that, when practiced, would
constitute, but for the license granted to Licensee pursuant to this Agreement,
an infringement of any claim or claims included within Licensor's Patent Rights.

      Section.1.7 "Net Sales" means billings by Licensee for (a) any Licensed
Product sold or leased, and (b) services performed using any Licensed Product or
Licensed Service, in all cases, net of the sum of the following items (where
applicable): (1) case, trade or quantity discounts actually allowed; (2) sales,
use, tariff, customs duties or other excise taxes directly imposed upon
particular sales; (3) outbound transportation charges prepaid or allowed; and
(4) allowances or credits to third parties for rejections or returns. A Licensed
Product and services performed using a Licensed Product or Licensed Services
shall be considered sold when billed

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       2
<PAGE>

out or invoiced or, if not invoiced, when delivered or performed. There shall be
no deductions from Net sales for costs of commissions or collections. Net Sales
shall not include billings for Licensed Products sold or services performed by
Licensee to any Affiliate unless such Affiliate is an end-user of any Licensed
Product or service performed using any Licensed Product or Licensed Method.

      Section 1.8 "Affiliate" means any person or entity that controls, is
controlled by, or is under common control with Licensee, directly or indirectly.
For purposes of this definition, "control" and its various inflected forms means
the possession, directly or indirectly, of the power to direct or cause the
direction of the management and policies of such person or entity, whether
through ownership of voting securities, by contract or otherwise.

                            ARTICLE 2. LICENSE GRANT

      Section 2.1 Subject to the terms and conditions set forth herein, Licensor
hereby grants to Licensee a license under Licensor's Patent Rights and Licensed
Technology to make, have made, use and sell any Licensed Product and to practice
any Licensed Services throughout the world where Licensor may lawfully grant
such a license.

      Section 2.2 The license granted in Section 2.1 hereof is expressly made
subject to Licensor's reservation of the right to practice under Licensor's
Patent Rights for educational and research purposes at the University of Utah.

      Section 2.3 Except as otherwise provided in Section 2.2 hereof, the
license granted in Section 2.1 shall be exclusive and worldwide and effective
until the * * *.

                              ARTICLE 3 SUBLICENSES

      Section 3.1 Licensor hereby grants to Licensee the right to enter into
sublicensing agreements with third parties (hereinafter referred to as
"Sublicensees") to make, have made, and sell any Licensed Product and to
practice any Licensed Method, provided that Licensee has current exclusive
rights thereto under this Agreement in the territory being sublicensed.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       3
<PAGE>

      Section 3.2 Any sublicense granted by Licensee to a Sublicensee shall
incorporate all of the terms and conditions of this Agreement, which shall be
binding upon each Sublicensee as if such sublicensee were a party to this
Agreement. Licensee shall pay to Licensor on any sublicense the royalty rate on
Net Sales by such Sublicensee at the same rate that would be due to Licensor
from Net Sales by Licensee, although Licensee is free to charge differential
rates to Sublicensees. In addition, Licensee shall pay to Licensor * * * of any
lump-sum fee or advance payment received by Licensee from any Sublicensee.

      Section 3.3 Licensee shall promptly (a) provide Licensor with a copy of
each sublicense granted by Licensee hereunder and any amendments thereto or
terminations thereof; (b) collect and guarantee payment of all royalties due
Licensor from Sublicensees; and (c) summarize and deliver copies of all reports
due to Licensee from Sublicensees.

                      ARTICLE 4 LICENSE ISSUE CONSIDERATION

      Section 4.1 Licensee shall grant to Licensor a non-refundable license
issue consideration of * * * position in Licensee upon execution of this
Agreement.

      Such issue consideration shall be deemed earned and immediately due upon
execution of this Agreement.

      Section 4.2 In addition, Licensee shall pay to Licensor a nonrefundable
license fee of * * * on or before * * *, or when Licensee first receives equity
funding of * * * or more, whichever is sooner. This fee is not an advance
against earned royalties.

                               ARTICLE 5 ROYALTIES

      Section 5.1 As additional consideration for the license under this
Agreement and subject to Section 6.2, Licensee shall pay to Licensor an earned
royalty of * * * in * * * and one and * * * of Net Sales of Licensed Products or
Services in * * *. Earned royalties shall accrue in each country * * *. Licensee
shall pay all royalties accruing to Licensor in U.S. Dollars within forty-five
(45) days following the calendar quarter in which Net Sales occur. No royalty
shall be

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       4
<PAGE>

payable with respect to Net Sales to any Affiliate unless such Affiliate is an
end-user of any Licensed Product or service performed using any Licensed Product
or Licensed Method.

      Section 5.2 Commencing on the first January 1 to occur after the six (6)
month period following the date of first occurrence of Net Sales, Licensee shall
pay to Licensor * * *:

             (a)     * * *          * * *

             (b)     * * *          * * *

             (c)     * * *          * * *

Licensee shall continue to pay * * * until * * *. Licensor shall fully credit
each payment * * * against any earned royalties payable by Licensee with respect
to the year in which the * * * is made.

      Section 5.3 If any patent or any claim thereof included within Licensor's
Patent Rights shall be found invalid by a court of competent jurisdiction and
last resort, from which decision no appeal may be taken, Licensee's obligation
to pay Licensor royalties based on such patent or claim or any claim patentably
indistinct therefrom shall be for a period of * * *. Licensee shall not,
however, be relieved from paying Licensor the applicable royalties that accrued
prior to the date of such decision or that are based on any of Licensor's Patent
Rights not the subject of such decision.

                            ARTICLE 6. DUE DILIGENCE

      Section 6.1 Upon execution of this Agreement, Licensee shall diligently
proceed with the development, manufacture, sale and use of Licensed Products
and/or Licensed Methods in order to make them readily available to the general
public as soon as possible on commercially reasonable terms.

      Section 6.2 Licensee shall perform the following obligations as part of
its due diligence activities hereunder:

      (a) Achieve Net Sales by * * *.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       5
<PAGE>

      Section 6.3 The above milestones shall be extendable for up to two (2)
years upon payment of * * * per year per.

      Section 6.4 Licensee shall exercise reasonable business judgment in
meeting its due diligence obligations hereunder.

      Section 6.5 Commencing on January 1, 1997 and on each January 1
thereafter, until the first occurrence of Net Sales, Licensee shall submit to
Licensor a written report covering Licensee's progress in (a) development and
testing of all, Licensed Research; (b) achieving the due diligence milestones
specified herein; and (c) preparing, filing, and obtaining of any approvals
necessary for marketing the Licensed Products and Licensed Methods.

                           ARTICLE 7. CONFIDENTIALITY

      Section 7.1 Licensee and Licensor acknowledge that they may provide
certain information to the other party about the Inventions that is considered
to be confidential. Licensee and Licensor shall take reasonable precautions to
protect such confidential information. Such precautions shall involve at least
the same degree of care and precaution that the recipient of such information
customarily uses to protect its own confidential information.

      Section 7.2 Licensee acknowledges that Licensor is subject to the Utah
Governmental Records Access and Management Act ("GRAMA"), Section 63-2-101 et
seq., Utah Code Ann. (1953), as amended. Licensor shall keep confidential any
information provided to Licensor by Licensee that Licensee considers
confidential, to the extent allowable under GRAMA and as provided in Section
53B-16-301 et seq., Utah Code Ann. In order to be eligible for such protection
under GRAMA, confidential information of Licensee disclosed to Licensor must be
in written or other tangible form, marked as proprietary, and accompanied by a
written claim by Licensee stating the reasons that such information must be kept
confidential.

                           ARTICLE 8 QUARTERLY REPORTS

      Section 8.1 Within forty-five (45) days after the calendar year in which
Net Sales first occur, and within 45 days after each calendar quarter
thereafter, Licensee shall provide Licensor

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       6
<PAGE>

with a written report detailing all sales and uses, if any, made of Licensed
Products and Licensed Methods during the preceding calendar quarter, and
detailing the amount of Net Sales made during such quarter and calculating the
royalties due pursuant to section 5.1 hereof. Each such report shall be signed
by an officer of Licensee (or the officer's designee).

      Section 8.2 In addition to the regular reports required by Section 8.1,
Licensee shall provide a written report to Licensor of the date of first
occurrence of Net Sales in each country within sixty (60) days of its
occurrence.

                  ARTICLE 9 PATENT PROSECUTION AND MAINTENANCE

      Section 9.1 Licensor shall diligently prosecute and maintain Licensor's
Patent Rights with legal counsel of its choice, after consultation with
Licensee. Licensor shall provide Licensee with copies of all relevant
documentation and keep Licensee informed, and apprised of the continuing
prosecution. Licensee shall keep any such documentation and information
confidential.

      Section 9.2 Licensee shall pay all costs and legal fees incurred by
Licensor in the preparation, prosecution and maintenance of Licensor's Patent
Rights, including without limitation, any taxes on such patent rights. Licensor
shall credit any costs and fees paid by Licensee pursuant to this Article 9
toward earned royalty payments due to Licensor for Net Sales in the country
where such patent costs were incurred. Notwithstanding the foregoing, no credit
may be applied toward the license issue fee or* * * royalty, and total credits
for costs and fees paid by Licensee pursuant to this Article 9 in any given
reporting period shall not be more than * * * of the royalty payment that would
otherwise be due. Unused credits may be carried forward indefinitely until used.

                            ARTICLE 10 PATENT MARKING

      Licensee shall mark all Licensed Products made, used or sold under the
terms of this Agreement, or their containers, in accordance with all applicable
patent marking laws.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       7
<PAGE>

                          ARTICLE 11 BOOKS AND RECORDS

      Licensee shall keep true and complete books and records containing an
accurate accounting of all data necessary for proper computation of royalties
and other payments hereunder. Licensee shall preserve such books and records for
five (5) years after the termination of this Agreement. Such books and records
shall be open to inspection by Licensor and its representatives, at Licensor's
expense, upon notice to Licensee, at reasonable times for the purpose of
verifying the accuracy of the quarterly reports and computations rendered by
Licensee.

                        ARTICLE 12 TERM OF THIS AGREEMENT

      This Agreement shall be in full force and effect from the date hereof
until * * *.

                       ARTICLE 13 TERMINATION BY LICENSOR

Section 13.1 If Licensee should (a) fail to deliver to Licensor any statement or
report required hereunder when due; (b) fail to make any payment at the time
that the same should be due; (c) violate or fail to perform any covenant,
condition, or undertaking of this Agreement to be performed by it hereunder; or
(d) file a bankruptcy action, or have a bankruptcy action against it, or become
insolvent, enter into a composition with creditors or have a receiver appointed
for it; then Licensor may give written notice of such default to Licensee. If
Licensee should fail to cure such default within thirty (30) days of such
notice, Licensor shall have the right to terminate this Agreement and any
licenses granted hereunder.

      Section 13.2 No termination of this Agreement by Licensor shall relieve
Licensee of its obligation to pay any royalty or license fees due or owing at
the time of such termination and pay all attorneys' fees and costs incurred by
Licensor in enforcing any obligation of Licensee or accrued right of Licensor
after termination. Articles 7 and 20 shall survive any termination of this
Agreement.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       8
<PAGE>

                       ARTICLE 14. TERMINATION BY LICENSEE

      Section 14.1 Licensee may terminate this Agreement at any time and from
time to time without cause, by giving written notice thereof to Licensor. Such
termination shall be effective ninety (90) days after such notice and all
Licensee's rights associated therewith shall cease as of that date.

      Section 14.2 Any termination pursuant to Section 14.1 shall not relieve
Licensee of any obligation or liability accrued hereunder prior to such
termination, or rescind or give rise to any right to rescind any payments made
or other consideration given to Licensor hereunder prior to the time such
termination becomes effective. Such termination shall not affect in any manner
any rights of Licensor arising under this Agreement prior to the date of such
termination.

      ARTICLE 15 DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION

      Upon expiration or termination of this Agreement by either party, Licensee
shall provide Licensor with a written inventory of all Licensed Products in
process of manufacture, in use or in stock. Licensee may dispose of any such
Licensed Products within the ninety (90)-day period following such expiration or
termination, provided, however, that Licensee shall pay royalties and render
reports to Licensor thereon in the manner specified herein.

                        ARTICLE 16. WARRANTY BY LICENSOR

      Section 16.1 Licensor warrants that it has the lawful right to grant the
license set forth in this Agreement.

      Section 16.2 EXCEPT AS EXPRESSLY PROVIDED IN SECTION 16.1, THE PARTIES
ACKNOWLEDGE AND AGREE THAT LICENSOR HAS MADE NO REPRESENTATIONS OR WARRANTIES,
EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL LICENSOR BE HELD

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       9
<PAGE>

RESPONSIBLE FOR ANY SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES ARISING OUT OF
THE USE OF PATENT RIGHTS, EVEN IF LICENSOR IS ADVISED IN ADVANCE OF THE
POSSIBILITY OF SUCH DAMAGES.

      Section 16.3 Nothing in this Agreement shall be construed as:

      (a)         a warranty or representation by Licensor as to the validity or
            scope of any Licensor's Patent Rights.

      (b)         a warranty or representation by Licensor that anything made,
            used, sold or otherwise disposed of pursuant to any license granted
            under this Agreement is or will be free from infringement of patents
            of third parties.

      (c)         an obligation by Licensor to bring or prosecute actions or
            suits against third parties for patent infringement, except as
            expressly provided in Article 17 hereof.

      (d)         conferring by implication, estoppel or otherwise any license
            or rights under any patents of Licensor other than Licensor's Patent
            Rights.

                             ARTICLE 17 INFRINGEMENT

      Section 17.1 If either party learns of a claim of infringement of or by
any of Licensor's Patent Rights licensed under this Agreement, that party shall
give written notice of such claim to the other party. Licensor shall then use
reasonable efforts to terminate such infringement. In the event Licensor fails
to abate the infringing activity within ninety (90) days after such written
notice or to bring legal action against the third party, Licensee may bring suit
for patent infringement, naming Licensor as nominal party plaintiff.

      Section 17.2 Any such legal action shall be at the expense of the party by
whom suit is filed (hereinafter referred to as the "Litigating Party"). Any
damages or costs recovered by the Litigating Party in connection with a legal
action filed by it hereunder, and remaining after the Litigating Party is
reimbursed for its costs and expenses reasonably incurred in the lawsuit, shall
be equally divided between Licensee and Licensor.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       10
<PAGE>

      Section 17.3 Licensee and Licensor shall cooperate with each other in
litigation proceedings instituted hereunder, provided that such cooperation
shall be at the expense of the Litigating Party, and such litigation shall be
controlled by the Litigating Party.

                                ARTICLE 18 WAIVER

      No waiver by either party hereto of any breach or default of any of the
covenants or agreements herein set forth shall be deemed a waiver as to any
subsequent and/or similar breach or default.

                            ARTICLE 19 ASSIGNABILITY

      This Agreement is binding upon and shall inure to the benefit of the
parties, their successors and assigns. Subject to Licensee's rights to
sublicense, as set forth in Article 3 hereof, Licensee may assign this Agreement
only with the written consent of Licensor.

                           ARTICLE 20 INDEMNIFICATION

      Licensee shall indemnify, hold harmless and defend Licensor, the
University of Utah, and their respective officers, employees and agents, against
any and all claims. suits, losses, damage, costs, fees and expenses (including
reasonable fees of attorneys) resulting from or arising out of exercise of any
license granted under this Agreement.

                            ARTICLE 21 LATE PAYMENTS

      In the event royalty payments or other fees are not received by Licensor
when due hereunder, Licensee shall pay to Licensor interest charges at the rate
of ten percent (10%) per annum on the total royalties or fees due for the
reporting period.

                               ARTICLE 22 NOTICES

      Any payment, notice or other communication required or permitted to be
given to either party hereto shall be in writing and shall be deemed to have
been properly given and effective: (a) on the date of delivery if delivered in
person during recipient's normal business hours; or (b) on the date of delivery
if delivered by courier, express mail service or first-class mail, registered

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       11
<PAGE>

or certified. Such notice shall be sent or delivered to the respective addresses
given below, or to such other address as either party shall designate by written
notice given to the other party as follows:

            In the case of Licensee:

            BIONIC TECHNOLOGIES, INC.
            1763 East 900 South
            Salt Lake City, UT 84108

            In the case of Licensor:

            UNIVERSITY OF UTAH RESEARCH FOUNDATION
            Technology Transfer Office
            421 Wakara Way, Suite 170
            Salt Lake City, UT 84108

            With a copy to:

            OFFICE OF GENERAL COUNSEL
            University of Utah
            309 Park Building
            Salt Lake City, Utah 84112

                             ARTICLE 23 FOREIGN LAWS

      Section 23.1 When required by local/national law, Licensee shall register
this Agreement, pay all costs and legal fees connected therewith, and otherwise
insure that the local/national laws affecting this Agreement are fully
satisfied.

      Section 23.2 Licensee shall comply with all applicable U.S. laws dealing
with the export of technology or technical information.

                            ARTICLE 24 GOVERNING LAW

      This Agreement shall be interpreted and construed in accordance with the
laws of the State of Utah, without application of any principles of choice of
laws.

                          ARTICLE 25 GENERAL PROVISIONS

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       12
<PAGE>

      Section 25.1 In the event of any controversy or claim between the parties
relating to this Agreement that is not settled by informal means, the same shall
be submitted to binding compulsory arbitration and judgment in Salt Lake City,
Utah pursuant to Title 78, Chapter 31a, Utah code Ann. (1953), as amended, and
shall be determined in accordance with the Commercial Arbitration Rules of the
American Arbitration Association to the extent such rules are not in conflict
with such law. All costs and expenses, including reasonable attorneys' fees, of
the prevailing party in connection with controversy or claim shall be borne by
the other party.

      Section 25.2 The headings of the several sections are inserted for
convenience of reference only and are not intended to be a part of or to affect
the meaning or interpretation of this Agreement.

      Section 25.3 This Agreement shall not be binding upon the parties until it
has been signed herein below by or on behalf of each party, in which event it
shall be effective as of the date first above written.

      Section 25.4 No amendment or modification of this Agreement shall be valid
or binding upon the parties unless made in writing and signed by both parties.
This Agreement may be signed in counterpart, each of which documents shall, when
taken together, constitute one and the same original document.

      Section 25.5 This Agreement embodies the entire understanding of the
parties and supersedes all previous communications, representations or
understandings, either oral or written, between the parties relating to the
subject matter, hereof.

      Section 25.6 The parties agree to execute and deliver all documents,
provide all information and take or forbear from taking all such action as may
be necessary or appropriate to achieve the purposes of this Agreement.

      Section 25.7 This Agreement may be signed in counterparts, each of which
when taken together shall constitute one fully executed document. Each
individual executing this Agreement on behalf of a legal entity does hereby
represent and warrant to each other person so signing that he or she has been
duly authorized to execute this Agreement on behalf of such entity.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       13
<PAGE>

      IN WITNESS WHEREOF, Licensor and Licensee have executed this Agreement by
their respective officers hereunto duly authorized, on the day and year
hereinafter written.

"LICENSEE"                              "LICENSOR"

BIONIC TECHNOLOGIES, INC.               UNIVERSITY OF UTAH
                                        RESEARCH FOUNDATION

By _________________________________    By _________________________________
             (Signature)                             (Signature)

Name _______________________________    Name _______________________________
             (Please Print)

Title ______________________________    Title ______________________________

Date _______________________________    Date _______________________________

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       14
<PAGE>

                   AMENDMENT TO THE LICENSE AGREEMENT BETWEEN
                     UNIVERSITY OF UTAH RESEARCH FOUNDATION
                                       AND
                        BIONIC TECHNOLOGIES INCORPORATED
                                       FOR

      * * *

      * * *

      * * *

      THIS AMENDMENT to a certain License Agreement is made and is effective as
of October 15, 1997, by and between The University of Utah Research Foundation,
having a principal place of business at 421 Wakara Way, Suite 170, Salt Lake
City, UT 84108, hereinafter referred to as Licensor and Bionic Technologies
Inc., having its principal place of business at 1763 East 900 South, Salt Lake
City, UT 84108, hereinafter referred to as Licensee.

                               W I T N E S S E T H

      WHEREAS, Licensor and Licensee have entered into a License Agreement dated
August 1, 1996 for * * * respectively hereinafter referred to as "License
Agreement"; and

      WHEREAS, Licensor has received the inventions entitled * * * respectively,
hereinafter referred to as "New Inventions"; and

      WHEREAS, Licensee would like incorporate the New Inventions in the above
License Agreement; and.

      WHEREAS Licensor is willing to grant to Licensee such a license to New
Inventions;

      NOW THEREFORE, for and in consideration of the covenants, conditions and
undertakings hereinafter set forth in the License Agreement, it is agreed by and
between the parties to add the New Inventions to Exhibit B of the License
Agreement.

      In all other respects the License Agreement shall remain unchanged.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

<PAGE>

      IN WITNESS WHEREOF, the parties have caused these presents to be signed in
duplicate by their duly authorized representatives.

BIONIC TECHNOLOGIES, INC.               UNIVERSITY OF UTAH
                                        RESEARCH FOUNDATION

By _________________________________    By _________________________________
             (Signature)                             (Signature)

Name _______________________________    Name _______________________________
             (Please Print)

Title ______________________________    Title ______________________________

Date _______________________________    Date _______________________________

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       2
<PAGE>

                                 AMENDMENT NO, 2
                        TO THE LICENSE AGREEMENT BETWEEN
                     UNIVERSITY OF UTAH RESEARCH FOUNDATION
                                       AND
                        BIONIC TECHNOLOGIES INCORPORATED
                                       FOR

* * *

      THIS AMENDMENT to a certain License Agreement is made and is effective as
of November 10, 1999 by and between the University of Utah Research Foundation,
having a principal place of business at 615 Arapeen Dr., Suite 110, Salt take
City, UT 84108, hereinafter referred to as Licensor and Bionic Technologies,
Inc., having its principal place of business at 1163 East 900 South, Salt Lake
City, UT 84108, hereinafter referred to as Licensee.

                              W I T N E S S E T H:

      WHEREAS, Licensor and Licensee have entered into a License Agreement dated
August 1, 1996 for * * *, as amended by Amendment 1, thereto dated October 15,
1997 respectively, hereinafter referred to as "License Agreement;" and

      WHEREAS, Licensor has received the invention entitled * * * respectively,
hereinafter referred to as "New Invention;" and

      WHEREAS Licensee would like to incorporate the New Invention in the above
License Agreement; and

      WHEREAS Licensor is willing to grant to Licensee such a license to the New
Invention;

                               A G R E E M E N T :

      NOW, THEREFORE, the parties agree as follows:

      1.) For and in consideration of the covenants, conditions and undertakings
hereinafter set forth in the License Agreement, it is agreed by and between the
parties to add the New Invention to Exhibit B of the License Agreement.

      2.) Amendment of Section 1.3. Section 1.3 of the License Agreement is
amended by deleting the sentence under Section 1.3 and replacing it with the
following:

      "'Licensed Technology'" means the technology and the intellectual property
associated with the Inventions listed in Exhibit 'A' and Exhibit 'B,' developed
by Dr. Richard Normann and his coworkers at the University of Utah."

      3.) In all other respects the License Agreement shall remain unchanged.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

<PAGE>

      IN WITNESS WHEREOF, the parties have executed this Amendment as of the
date first above written:

LICENSEE:                               LICENSOR:

BIONIC TECHNOLOGIES, INC.               UNIVERSITY OF UTAH
                                        RESEARCH FOUNDATION

By: _______________________________     By: _______________________________

       Brian W. Hatt, President              Richard K. Koehn. Ph.D.
                                             President

Date: _____________________________     Date: _____________________________

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       2
<PAGE>

                            BIONIC TECHNOLOGIES, INC.

                      AMENDMENT NO. 3 TO LICENSE AGREEMENT

      THIS AMENDMENT NO. 3 TO LICENSE AGREEMENT (the "AMENDMENT") is made as of
February 7, 2002 by and between BIONIC TECHNOLOGIES, LLC., a Utah limited
liability company, having its principal place of business at 1763 East 900
South, Salt Lake City, UT 84108, hereinafter referred to as (the "LICENSEE"),
and the UNIVERSITY OF UTAH RESEARCH FOUNDATION, a Utah non-profit corporation,
having its principal place of business at 615 Arapeen Drive, Suite 110, Salt
Lake City, Utah 84108, hereinafter referred to as (the "LICENSOR").

                                    RECITALS

      WHEREAS, the LICENSEE's predecessor in interest, Bionic Technologies, Inc.
("Licensee's Predecessor"), and the LICENSOR executed the AGREEMENT dated August
1, 1996 ("Original License"), pursuant to which LICENSEE took a license to
certain inventions, generally characterized as: * * * ; and

      WHEREAS, LICENSEE'S Predecessor and LICENSOR amended the Original License
by means of an amendment dated October 15, 1997 ("Amendment No. 1") and an
amendment dated November 10, 1999 ("Amendment No. 2") (the Original Licensee, as
amended by the Amendment No. 1 and the Amendment No. 2, being herein referred to
as the "Amended License"); and

      WHEREAS, as of January 1, 2001, LICENSEE'S predecessor assigned the
Amended License to LICENSEE with LICENSOR'S consent and thereupon LICENSEE
assumed all obligations thereunder; and

      WHEREAS, the LICENSEE and the LICENSOR agree to amend the Amended License
to make the following changes and additions.

      NOW, THEREFORE, in consideration of the foregoing and the promises and
covenants contained herein, the sufficiency of which is hereby acknowledged, the
parties agree as follows:

              I. MODIFICATION TO THE TERMS OF THE AMENDED LICENSE

      1. Section 1.2 of the Amended License is hereby replaced in its entirety
with the following:

      "Section 1.2 "FIELD OF USE" means all medical and research applications in
      animal and human subjects

      2. Section 2.1 of the Amended License is hereby replaced in its entirety
with the following:

      "Section 2.1 Subject to the terms and conditions set forth herein,
      Licensor hereby grants to Licensee an exclusive, worldwide license under
      Licensee's Patent Rights and

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

<PAGE>

      Licensed Technology to make, have made, use and sell any Licensed Product
      and to practice any Licensed Services in the FIELD OF USE.

      3. Section 3.2 of the Amended License is hereby replaced in its entirety
with the following:

      "Section 31 Any sublicense granted by Licensee to a Sublicensee shall
      incorporate all of the terms and conditions of this Agreement, which shall
      be binding upon each Sublicensee as if such Sublicensee were a party to
      this Agreement. Licensee shall pay to Licensor on any sublicense a
      percentage of the gross consideration received by the Licensee from the
      Sublicensee for grant of the sublicense, whether that consideration comes
      in the form of up-front license fees, royalties, milestone payments or in
      any other form, except as noted below in this Section 3.1. The percentage
      of gross consideration due to Licensor as described herein shall be
      determined according to the following chart:

<TABLE>
<CAPTION>
YEAR*                PERCENTAGE
-----                ----------
<S>                  <C>
* * *                  * * *
* * *                  * * *
* * *                  * * *
</TABLE>

      *"YEAR" shall mean the year in which the consideration is received by the
      Licensee from the Sub-licensee as specified by the dates, beginning on * *
      *.

      Licensee shall not be obligated to pay Licensor for consideration received
      from a Sublicensee on the following items:

            a)    payments for training Sublicensees;

            b)    payments for research and development;

            c)    payments for fees and expenses associated with patent
                  prosecution;

            d)    payments for advance commitments of the purchase of products
                  in excess of the purchase price (for which royalties would be
                  paid in accordance with the terms of Article 5);

            e)    payments in respect of equity investments in Licensee; and

            f)    payments in respect of loans to Licensee.

      4. A new Section 3.4 is hereby added to the Amended License as follows:

      "Section 3.4 In the event that Licensor or Licensee receives a written
      request from a capable third party for a license to use the Licensor's
      Patent Rights or Licensed Technology in a subfield of use which does not
      compete with the Licensed Products or Licensed Services already offered
      for sale by Licensee or in the process of being developed by Licensee so
      as to be available for sale within one (1) year as demonstrated by
      Licensee to the reasonable satisfaction of Licensor, Licensee agrees to
      negotiate in good faith to grant a sublicense to said third party. If such
      negotiation has not been successfully completed within six (6) months from
      the date Licensee first receives such request, Licensor shall have the
      right to grant a license to said party for said subfield of use under
      substantially similar, or at Licensor's discretion, less favorable, terms
      to those

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                        2
<PAGE>

      contained in this Agreement provided that the royalty rate shall be no
      lower than that contained herein. If Licensor grants a license under this
      provision, Licensor agrees to share * * * of its net royalties, net
      milestone payments and net license fees with Licensee.

      5. Section 5.1 of the Amended License is hereby amended in part by
replacing the term "* * *" with the term "* * *."

      6. Section 5.3 of the Amended License is hereby amended by replacing it in
its entirety with the following language:

      "Section 5.3 If any patent or claim thereof included within Licensor's
      Patent Rights shall be found invalid by a court of competent jurisdiction
      and last resort, from which decision no appeal may be taken, Licensee's
      obligation to pay Licensor royalties based on such patent or claim or any
      claim patentably indistinct therefrom shall cease as of that date.
      However, Licensee shall not be relieved from paying Licensor the
      applicable royalties that accrued prior to the date of such decision or
      that are based on any of Licensor's Patent Rights not the subject of such
      a decision."

      7. Section 4.2 of the Amended License is hereby replaced in its entirety
with the following:

      "Section 4.2 In addition, Licensee shall pay to Licensor a non-refundable
      license fee of * * * on a deferred and contingent basis as described
      below, but no later than December 31, 2003. In order to satisfy this
      obligation, Licensee shall pay Licensor * * * of all investments (equity
      or long-term debt) in Licensee, when it receives such an investment, up to
      a cumulative investment of * * *. If Licensee has not paid Licensor the
      total license fee of * * * by December 31, 2003, the remainder shall be
      due in full on that date.

      8. Article 17 of the Amended License is hereby replaced in its entirety
with the following:

      "ARTICLE 17. INFRINGEMENT

            Section 17.1 If either party learns of a claim of infringement of or
      by any of Licensor's Patent Rights licensed under this Agreement, that
      party shall give written notice of such claim to the other party. Licensee
      shall then use reasonable efforts to terminate such infringement. In the
      event Licensee fails to abate the infringing activity within ninety (90)
      days after such written notice or Licensee fails to bring legal action
      against the third party within a reasonable time, Licensor may bring suit
      for patent infringement. No settlement, consent judgment or other
      voluntary final disposition of the suit may be entered into without the
      consent of Licensor, which consent shall not be unreasonably withheld.

            Section 17.2 Any such legal action shall be at the expense of the
      party by whom suit is filed, hereinafter referred to as the "Litigating
      Party". Any damages or costs recovered by the Litigating Party in
      connection with a legal action, filed by it hereunder, and remaining after
      the Litigating Party is reimbursed for its costs and expenses

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       3
<PAGE>

      reasonably incurred in the lawsuit, and after any royalties or other
      payments due to Licensor under Articles 3, 4, and 5 are paid, shall be
      divided between Licensee and Licensor with 25% going to Licensor and 75%
      going to Licensee.

            Section 17.3 Licensee and Licensor shall cooperate with each other
      in litigation proceedings instituted hereunder, provided that such
      cooperation shall be at the expense of the Litigating Party, and such
      litigation shall be controlled by the Litigating Party."

      9. Article 19 of the Amended License is hereby replaced in its entirety
with the following:

            "This Agreement is binding upon and shall inure to the benefit of
      the parties, their successors and assigns. Subject to Licensee's rights to
      sublicense, as set forth in Article 3 hereof, Licensee may assign this
      Agreement only with the written consent of Licensor, which consent shall
      not be unreasonably withheld, or upon the sale or assignment of all or
      substantially all of the assets of Licensee to which this license
      Agreement relates."

      10. Article 22 of the Amended License shall be amended in part by
replacing subpart (b) thereof and the addresses for Licensee and Licensor set
forth therein with the following while the remainder of Article 22 shall be
unchanged:

      "(b) on-the date of delivery if delivered by courier, express mail service
      or fast-class mail, registered or certified, or by fax."

      As to the addresses:

            "In the case of Licensee:

            BIONIC TECHNOLOGIES, LLC.
            1763 East 900 South
            Salt Lake City, UT 84108
            FX: 801-582-9909;

            In the case of Licensor

            University of Utah Technology Transfer Office
            615 Arapeen Drive, Suite 110
            Salt Lake City, UT 84108
            FX: 801-581-7538"

                      II. CONSIDERATION FOR THIS AMENDMENT

      1. In consideration for this AMENDMENT, upon execution of this AMENDMENT,
LICENSEE shall:

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       4
<PAGE>

      issue to LICENSOR a warrant to purchase * * * units of Interests in
      LICENSEE. That warrant shall be exercisable by LICENSOR for the price of *
      * * per unit of Interests at any time after June 30, 2002 and prior to
      July 1, 2007.

                               III. INTERPRETATION

      1. All of the provisions of Article 25 of the Amended License are hereby
incorporated into this Section III as though set forth herein in full and shall
govern the interpretation of this AMENDMENT

      2. Except as otherwise amended by this AMENDMENT, the Amended License
shall remain in full force and effect,

IN WITNESS WHEREOF, the parties have executed this AMENDMENT to the Amended
License as of the date fast above written.

"LICENSEE"                              "LICENSOR"

BIONIC TECHNOLOGIES, LLC.               UNIVERSITY OF UTAH
                                        RESEARCH FOUNDATION

By _______________________________      __________________________________
             (Signature)                             (Signature)

Name: Brian W. Hart                     Name: Raymond F. Gesteland

Title: President                        Title: President

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       5
<PAGE>

                       ASSIGNMENT AND ASSUMPTION AGREEMENT

      This Assignment and Assumption Agreement is executed as of the 13th day of
August, 2002 by and between Bionic Technologies, LLC, a Utah limited liability
company ("Assignor"), and Cyberkinetics, Inc., a Delaware corporation
("Assignee").

      WHEREAS, Assignor and Assignee are parties to that certain Contribution
Agreement dated as of the date hereof (the "Contribution Agreement"), provided
for the purchase by Assignee of substantially all of the assets, properties,
rights and business as a going concern of Assignor and the assumption by
Assignee of certain of the liabilities of Assignor. All capitalized terms used
herein which are not defined herein shall have the meanings specified in the
Contribution Agreement.

      WHEREAS, Assignor is the licensee under that certain License Agreement
dated as of August 1, 1996, as amended, between Assignor and the University of
Utah Research Foundation, as licensor ("Licensor"), covering inventions * * *
(the "License").

      WHEREAS, Assignor proposes to assign the License to Assignee and Licensor
has consented in writing to such assignment.

      NOW, THEREFORE, for and in consideration of the mutual covenants contained
in the Contribution Agreement and other good and valuable consideration, receipt
of which is hereby acknowledged, Assignor hereby grants, bargains, sells,
assigns, transfers and sets over to Assignee and its successors and assigns all
of the right, title and interest of Assignor in, to and under the License.

      TO HAVE AND TO HOLD, the same unto Assignee, its legal representatives,
successors and assigns from and after the date hereof, subject, however, to the
terms, covenants, conditions and provisions of the License.

      Assignee hereby accepts this Agreement subject to the terms and conditions
herein contained and does hereby assume, without exculpation, as of the date
hereof, and becomes responsible for and agrees to perform, discharge, fulfill
and observe all of the licensee's obligations, liabilities, covenants,
conditions and provisions under the License accruing from before and after the
date hereof with the same force and effect as if Assignee were the original
licensee thereunder, and Assignee agrees to be liable for the observation and
performance thereof from and after the date hereof.

      Assignor agrees to protect, defend, indemnify and hold and save harmless
Assignee from and against any and all Liabilities relating to the License only
to the extent that Assignor has agreed to indemnify Assignee in Section 9 of the
Contribution Agreement.

      Assignee agrees to protect, defend, indemnify and hold and save harmless
Assignor from and against any and all Liabilities relating to the License only
to the extent that Assignee has agreed to indemnify Assignor in Section 9 of the
Contribution Agreement.

      This Agreement is made without recourse or warranty except as set forth in
the Contribution Agreement.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

<PAGE>

      This Agreement shall be binding upon and shall inure to the benefit of
Assignor and Assignee and their respective legal representatives, heirs,
successors and assigns.

      IN WITNESS WHEREOF, Assignor and Assignee have executed this Agreement as
of the date first set forth above,

                                        ASSIGNOR:

                                        BIONIC TECHNOLOGIES, LLC

                                        By: ________________________________
                                            Name:
                                            Title:

                                        ASSIGNEE:

                                        CYBERKINETICS, INC.

                                        By: ________________________________
                                            Name:
                                            Title:

APPROVED AND ACCEPTED:

UNIVERSITY OF UTAH RESEARCH FOUNDATION

By: _________________________________
     Signature

Print name: _________________________

Title: ______________________________

Date: _______________________________

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                        2<PAGE>

                                                                    EXHIBIT 10.6

                           EXCLUSIVE LICENSE AGREEMENT

      THIS LICENSE AGREEMENT is made and entered into as of this 28th day of
August, 2002 (the "Effective Date") by and between EMORY UNIVERSITY, a
non-profit Georgia corporation with offices located at 1380 South Oxford Road,
N.E., Atlanta, Georgia 30322 (hereinafter referred to as "EMORY"), and
CYBERKINETICS, INC., a for-profit Delaware corporation with offices located at
109 Hazard Avenue, Providence, RI 02906 (hereinafter referred to as
"CYBERKINETICS").

                                   WITNESSETH

      WHEREAS, EMORY is the assignee of all right, title, and interest in
certain inventions developed by an employee of EMORY and is responsible for the
protection and commercial development of such inventions; and

      WHEREAS, Donald R. Humphrey, Ph.D., is an employee of EMORY and is named
as sole inventor (hereafter referred to as the "Inventor") in United States
Patent No. * * * for * * *, and

      WHEREAS, CYBERKINETICS has the necessary expertise and will, as
appropriate, acquire the resources reasonably necessary to fully develop, obtain
approval for, and market products based upon the inventions claimed in the
above-referenced patent and the know-how not covered by the patent and licensed
hereunder; and

      WHEREAS, EMORY wants to have such inventions developed, commercialized,
and made available for use by the public; and

      WHEREAS, EMORY and CYBERKINETICS entered into that certain "Terms for
EMORY-CYBERKINETICS License Agreement" dated July 11, 2002 whereby EMORY and
CYBERKINETICS agreed to close the license between EMORY and CYBERKINETICS and a
stock purchase between EMORY and CYBERKINETICS for CYBERKINETICS to issue a
certain amount of its equity to EMORY based on the terms agreed upon therein;
and

      WHEREAS, EMORY desires to grant, and CYBERKINETICS desires to receive, an
exclusive, worldwide license to make, have made, import, use, offer to sell and
sell products based on or incorporating the inventions;

      NOW, THEREFORE, for and in consideration of the mutual covenants and the
premises herein contained, the parties, intending to be legally bound, hereby
agree as follows.

                             ARTICLE 1. DEFINITIONS

      The following terms as used herein shall have the following meaning:

      1.1 "Affiliate" shall mean any corporation or non-corporate business
entity, which controls, is controlled by, or is under common control with a
party to this Agreement. A corporation or non-corporate business entity shall be
regarded as in control of another corporation if it owns, or

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

<PAGE>

directly or indirectly controls, at least fifty (50%) percent of the voting
stock of the other corporation, or (i) in the absence of the ownership of at
least fifty (50%) percent of the voting stock of a corporation or (ii) in the
case of a non-corporate business entity, or non-profit corporation, if it
possesses, directly or indirectly, the power to direct or cause the direction of
the management and policies of such corporation or non-corporate business
entity, as applicable.

      1.2. "Agreement" or "License Agreement" shall mean this Agreement,
including all APPENDICES attached to this Agreement.

      1.3. "Dollars" shall mean United States dollars.

      1.4 "EMORY" shall mean EMORY University.

      1.5. "FDA" shall mean (a) the United States Food and Drug Administration
or successor entity thereto, and (b) any other foreign agency or commission
performing comparable functions where specifically specified in this Agreement.

      1.6. "Field of Use" shall mean all fields.

      1.7. "Indemnitees" shall mean EMORY, its directors, employees and
students, and their heirs, executors, administrators, successors and legal
representatives.

      1.8. "Licensed Know-How" shall mean all technical information and data,
other than the Licensed Patents, whether or not presently known or learned,
invented, or developed by the Inventor or any employees of EMORY working under
the Inventor's direct supervision, prior to the date of this agreement and while
they were under a duty to assign intellectual property rights to EMORY, to the
extent that (a) such technical information and data are useful for the
manufacture, use, importation, offer for sale or sale of any Licensed Product;
(b) EMORY possesses the right to license the use of such information and data to
CYBERKINETICS for commercial purposes without incurring financial or other
non-contingent, material obligations to any third party and without breaching
any obligations of confidentiality with any such party; and (c) such information
and data is not presently owned by CYBERKINETICS and does not in the future
become publicly known other than through disclosure by CYBERKINETICS.

      1.9. "Licensed Patents" shall mean U.S. Patent No. * * * for "* * *"
Issued * * *, together with any and all substitutions, extensions, divisionals,
continuations, continuations-in-part, which issue thereon anywhere in the world,
including reexamined and reissued patents and any extension of the term of any
such patent (including supplementary protection certificates) and all
corresponding foreign equivalents.

      1.10. "Licensed Products" shall mean any products, the manufacture, use,
importation, offer for sale or sale of which incorporate Licensed Technology, or
which would, absent the licenses granted in this Agreement, infringe any Valid
Claim included in any Licensed Patent.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       2
<PAGE>

      1.11. "Licensed Technology" shall mean the Licensed Patents and the
Licensed Know-How

      1.12. "Licensed Territory" shall mean the world.

      1.13. "Net Sales" shall mean gross amounts invoiced for "End Sales" (as
defined below) of a Licensed Product less the sum of (i) trade, quantity and
cash discounts actually allowed or paid, (ii) refunds, rebates, chargebacks,
retroactive price adjustments (including Medicaid, managed care and similar
types of rebates) and service allowances, (iii) credits or allowances given or
made for rejections or returns of previously sold products or for wastage
replacement actually taken or allowed, (iv) taxes, duties or other governmental
charges levied on or measured by the billing amount, as adjusted for rebates and
refunds, and (v) charges for shipping, freight and insurance directly related to
the distribution of the Licensed Product (excluding amounts reimbursed by third
party customers). End Sales shall mean all sales of any Licensed Product by
CYBERKINETICS, its Affiliates, or its Sublicensees other than sales ("Excluded
Sales") to CYBERKINETICS, an Affiliate or a Sublicensee, provided, however, that
End Sales shall include the sale of any Licensed Product to CYBERKINETICS, an
Affiliate or a Sublicensee where the purchaser of such Licensed Product is the
ultimate end-user of such Licensed Product and such Licensed Product is used by
such purchaser for commercial purposes to generate revenue from one or more
third parties, as opposed to use for research, development, manufacturing,
quality control, testing or similar uses in connection with the development or
commercialization of any Licensed Product. Sales of a Licensed Product for use
in conducting clinical trials of such Licensed Product in a country of the
Licensed Territory in order to obtain regulatory approval of such Licensed
Product in such country shall be included in Net Sales calculations only to the
extent that the amount included in such Net Sales exceeds the fully loaded cost
incurred by the party supplying such Licensed Product to supply such Licensed
Product.

      If a Licensed Product (a) consists of both (i) components causing such
product to be a Licensed Product and (ii) other components. or (b) is sold
together with one or more other products for a single invoiced price (e.g.,
where a product is a medical device comprised of one component that is Licensed
Product and other components that are not Licensed Products, or where a medical
device that is a Licensed Product is packaged for sale with a second medical
device that is not a Licensed Product) (each, a "Combination Sale"), the Net
Sales for such Licensed Product shall be the portion of such Combination Sale
properly allocable to such Licensed Product, determined as follows.

      Except as provided below, the Net Sales for a Licensed Product sold in
such a Combination Sale shall equal the gross amount invoiced for sale of the
Licensed Product and any and all other products or components, as the case may
be, included in such Combination Sale, reduced by the adjustments specified
above in the definition of Net Sales (the "Net Combination Sale Amount"),
multiplied by the fraction A/(A+B), where:

            * * *

      In the event that CYBERKINETICS, its Affiliate or Sublicensee, as
applicable, separately sells the Licensed Product included in a Combination Sale
in a country, but does not separately sell

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       3
<PAGE>

all of the other products or components, as the case may be, included in such
Combination Sale in such country, the calculation of "Net Sale" resulting from
such Combination Sale shall be determined by multiplying the Net Combination
Sale Amount by the fraction A/C where:

            * * *

      In the event that CYBERKINETICS, its Affiliate or Sublicensee, as
applicable, does not separately sell the Licensed Product contained in a
Combination Sale in the country where such Combination Sale occurs, but does
separately sell all of the other products or components, as the case may be,
included in the Combination Sale in such country, the calculation of Net Sales
resulting from such Combination Sale shall be determined by multiplying the Net
Combination Sale Amount by the fraction (C-D)/C, where:

            * * *

      Where the calculation of Net Sales resulting from a Combination Sale in a
country cannot be determined by any of the foregoing methods, the calculation of
Net Sales for such Combination Sale shall be * * *.

      1.14. "Person" shall mean any natural person or legal entity.

      1.15. "Regulatory Approval" or "Regulatory Registration" shall mean, in
relation to any Licensed Product, such approvals by the regulatory authorities
in a given country (including pricing approvals) as may be legally required
before such Licensed Products may be commercialized or Sold in such country.

      1.16. "Sale" or "Sold" shall mean the sale, lease, transfer, exchange, or
other disposition of Licensed Products to a third party whether by gift or
otherwise by CYBERKINETICS, its Affiliates, Sublicensees, distributors or any
third party authorized by CYBERKINETICS to make such sale, transfer, exchange or
disposition. Sales of Licensed Products shall be deemed consummated upon the
first to occur of: (a) receipt of payment from the purchaser; (b) delivery of
Licensed Products to the purchaser or a common carrier; (c) release of Licensed
Products from consignment; (d) if deemed Sold by use, when first put to such
use; or (e) if otherwise transferred, exchanged, or disposed of, whether by gift
or otherwise, when such transfer, exchange, gift, or other disposition occurs.
Notwithstanding the foregoing definition of Sale, to the extent CYBERKINETICS
distributes any Licensed Product under a treatment trial or other expanded
access program at a sales price that exceeds its fully absorbed cost therefor,
such excess shall be deemed to be a Sale for which royalties are payable in
accordance with the other terms hereof.

      1.17. "Sublicensee" shall mean any Person to whom CYBERKINETICS grants a
sublicense of some or all of the rights granted to CYBERKINETICS under this
Agreement.

      1.18. "U.S. 510 (k)" shall mean Article 510 (k) of the Food, Drug and
Cosmetic Act also known as Premarket Notification (PMN), corresponding
application or its equivalent.

      1.19. "U.S. IDE" shall mean Investigational Device Exemption,
corresponding applications or its equivalent.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       4
<PAGE>

      1.20. "U.S. Government Licenses" shall mean the non-exclusive license to
the U.S. Government directly, or acting through one of its recognized agencies.

      1.21. "Valid Claim" shall mean an issued claim of any unexpired patent or
claim of any pending patent application included among the Licensed Patents,
which has not been held unenforceable, unpatentable or invalid by a decision of
a court or governmental body of competent jurisdiction, unappealable or
unappealed within the time allowed for appeal, which has not been rendered
unenforceable through disclaimer or otherwise, which has not been donated to the
public, and which has not been lost through an interference proceeding.

                           ARTICLE 2. GRANT OF LICENSE

      2.1. License. Subject to the terms and conditions of this Agreement, EMORY
hereby grants CYBERKINETICS and its Affiliates an exclusive, sublicenseable,
royalty-bearing license under EMORY's interests and rights in the Licensed
Technology to make, have made, use, import, offer for sale, and sell Licensed
Products in the Licensed Territory and in the Licensed Field during the term of
this Agreement.

      2.2. Government Rights. The license granted in Article 2.1 above is
subject to the U.S. Government Licenses and other rights retained by the United
States in inventions developed by nonprofit institutions with the support of
federal funds. These rights are set forth in 35 USCA Section 201 et seq. and 37
CFR 401 et seq., which may be amended from time to time by the Congress of the
United States or through administrative procedures.

      2.3. Retained License. The license granted in Article 2.1 above is further
subject to a right and license retained by EMORY on behalf of itself and its
Affiliates to practice the Licensed Technology for EMORY's non-commercial
research and educational purposes only; provided, however, that nothing in this
Article 2.3 shall limit in any way the Inventor's rights under the "research
exception" under common law to practice the Licensed Technology solely for
non-commercial research and educational purposes.

      2.4. Sublicenses. CYBERKINETICS shall have the right to grant sublicenses
consistent with its diligence obligations under Article 6 hereof. CYBERKINETICS
shall notify EMORY at least twenty (20) days prior to entering into any
sublicense agreement and will provide EMORY with copies of all sublicense
agreements within ninety (90) days of their execution date. CYBERKINETICS
understands that flipping the Licensed Technology in the form of a sublicense
without adding value (i.e. without itself having first undertaken further
development activity or requiring that its Sublicensee undertake further
development activities) to the Licensed Technology is prohibited and EMORY
retains the right to disapprove such sublicensing activities. CYBERKINETICS
shall remain responsible to EMORY for the payment of all fees and royalties due
under this Agreement, whether or not such payments are made to CYBERKINETICS,
its Affiliates or its Sublicensees. CYBERKINETICS shall include in any
sublicense granted pursuant to this Agreement a provision requiring the
Sublicensee to (i) abide by the confidentiality obligations herein, (ii)
indemnify EMORY and (iii) maintain liability insurance coverage to the same
extent that CYBERKINETICS is so required pursuant to Article 10.3 of this
Agreement. CYBERKINETICS shall not grant any rights to any Sublicensee, which
are

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       5
<PAGE>

inconsistent with the rights granted to and obligations of CYBERKINETICS
hereunder. Any act or omission of a Sublicensee, which would be a breach of this
Agreement if performed by CYBERKINETICS, shall be deemed to be a breach by such
Sublicensee of its sublicense agreement.

      If this Agreement terminates for any reason, any Sublicensee shall, from
the effective date of such termination, automatically become a direct licensee
of EMORY with respect to the rights originally sublicensed to it by
CYBERKINETICS, provided such Sublicensee did not cause the termination of this
Agreement and such Sublicensee agrees to comply with all of the terms of this
Agreement and assumes the responsibilities of CYBERKINETICS hereunder to the
extent applicable from the rights originally sublicensed to it by CYBERKINETICS.

      2.5. No Implied License. The license and rights granted in this Agreement
shall not be construed to confer any rights upon CYBERKINETICS by implication,
estoppel, or otherwise as to any technology not specifically identified in this
Agreement as Licensed Patents or Licensed Know-How.

                     ARTICLE 3. ROYALTIES AND OTHER PAYMENTS

      3.1. Signing Fee. CYBERKINETICS shall, within thirty (30) days of
execution of the License Agreement, pay EMORY the sum of * * * as a signing fee.

      3.2. Running Royalties for Sale of Licensed Products by CYBERKINETICS or
its Affiliates or Sublicensees. CYBERKINETICS or its Affiliates or Sublicensees
shall pay EMORY royalty equal to the Applicable Percentage of Net Sales of
Licensed Products by CYBERKINETICS, its Affiliates or Sublicensees in the
Territory. The Applicable Percentage with respect to * * *of such Net Sales in
any fiscal year of CYBERKINETICS shall be * * * and with respect to all
additional such Net Sales in any such fiscal year shall be * * *, subject to
adjustment as provided below.

            (a) The running royalties payable under this Article 3.2 on any Net
Sales of Licensed Products shall be reduced by * * * of any royalties payable to
third parties by CYBERKINETICS, its Affiliates or its Sublicensees on the same
Net Sales of Licensed Products. Absent the written consent of EMORY, the
reduction in royalty rates specified by this subparagraph (a) shall not operate
to reduce the running royalty rates payable by CYBERKINETICS, its Affiliates and
its Sublicensees to EMORY during any fiscal year of CYBERKINETICS to less than
* * * of Net Sales of Licensed Products during such fiscal year * * * in the
case of Know-How Only Net Sales (as defined below)).

            (b) Licensee's obligation to pay a running royalty on a Licensed
Product shall terminate upon the later of (i) * * * and (ii) * * *.

            (c) All royalty payments due to EMORY hereunder shall be subject to
any tax withholding required under the laws of any country, and all payments to
EMORY hereunder shall be net of such taxes.

            (d) The Applicable Percentage shall be reduced by * * * with respect
to any Net Sales with respect to any Licensed Product in a particular country
that is a Licensed Product in such

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       6
<PAGE>

country solely because such Licensed Product incorporates Licensed Know-How and
is not covered by a Valid Claim ("Know-How Only Net Sales").

      3.3. Milestone Payments. Upon the achievement of each event set forth
below, on a Licensed Product-by-Licensed Product basis, CYBERKINETICS shall pay
EMORY the amount indicated below, no later than thirty (30) days from the
occurrence of the indicated event:

<TABLE>
<CAPTION>
Event                                              Milestone
-----                                              ---------
<S>                                                <C>
* * *                                                 * * *

* * *                                                 * * *
</TABLE>

Once CYBERKINETICS has made a payment under this Article 3.3 upon the occurrence
of U.S. IDE Approval with respect to a particular Licensed Product,
CYBERKINETICS will not be obligated to make any payments under this Article 3.3
with respect to any other U.S. IDE Approval with respect to a Licensed Product
that is substantially similar to such Licensed Product or that represents only
an enhanced or improved version of such Licensed Product. CYBERKINETICS will be
obligated to make only one milestone payment under this Article 3.3 with respect
to each * * *, regardless of the number of Licensed Products that are sold
* * *.

      3.4. Minimum Annual Royalties. Beginning on the * * * anniversary of the
Effective Date, on each anniversary of the Effective Date CYBERKINETICS shall
pay EMORY a minimum annual royalty of * * *. CYBERKINETICS may credit the
minimum annual royalty paid under this Article 3.4 against any royalties that
become payable to EMORY under Article 3.2 during the year to which such minimum
annual royalty relates.

      3.5. Reimbursement for Patent Costs. CYBERKINETICS shall, within fifteen
(15) days of execution of this Agreement, pay EMORY the sum of * * * to
reimburse EMORY for costs incurred by EMORY as of the execution date of the
License Agreement in prosecuting and defending the Licensed Patents.

      3.6. Equity. CYBERKINETICS shall issue to EMORY * * * shares of
CYBERKINETICS common stock. The Equity transaction between CYBERKINETICS and
EMORY shall be fully specified in a separate Stock Purchase Agreement made and
entered into as of the Effective Date of this Agreement.

                        ARTICLE 4. REPORTS AND ACCOUNTING

      4.1. Royalty Reports and Records. During the term of this Agreement,
CYBERKINETICS shall furnish, or cause to be furnished to EMORY, written reports
relating to each of CYBERKINETICS, CYBERKINETICS 's Affiliates and Sublicensees
fiscal quarters showing:

                  (i) the gross selling price of all Licensed Products Sold by
CYBERKINETICS, its Affiliates and Sublicensees, in each country of the Licensed
Territory

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       7
<PAGE>

during the reporting period, together with the calculations of Net Sales in
accordance with Article 1.13;

                  (ii) the royalties payable in Dollars, which shall have
accrued hereunder with respect to such reporting period in respect to such Net
Sales;

                  (iii) the exchange rates, if any, used in determining the
royalties payable;

                  (iv) a summary of all reports provided to CYBERKINETICS by
CYBERKINETICS' Sublicensees;

                  (v) the occurrence of any event triggering a Milestone Payment
obligation in accordance with Article 3.3.

Reports shall be made semiannually until the first Sale of a Licensed Product
and quarterly thereafter. Semiannual reports shall be due within thirty (30)
days of the close of every second and fourth CYBERKINETICS fiscal quarter.
Quarterly reports shall be due within thirty (30) days of the close of every
CYBERKINETICS fiscal quarter. CYBERKINETICS shall keep accurate records in
sufficient detail to enable royalties and other payments payable hereunder to be
determined. CYBERKINETICS shall be responsible for all royalties and late
payments that are due to EMORY that have not been paid by CYBERKINETICS'
Affiliates and Sublicensees. CYBERKINETICS' Sublicensees shall have, and shall
be notified by CYBERKINETICS that they have, the option of making any royalty
payment directly to EMORY.

      4.2. Right to Audit. EMORY shall have the right, upon prior notice to
CYBERKINETICS, not more than once in each CYBERKINETICS fiscal year, through an
independent public accountant selected by EMORY and acceptable to CYBERKINETICS,
which acceptance shall not be unreasonably refused, to have access during
CYBERKINETICS' normal business hours as may be reasonably necessary to verify
the accuracy of the royalty reports required to be furnished by CYBERKINETICS
pursuant to Article 5.1 of the Agreement. CYBERKINETICS shall include in any
sublicenses granted pursuant to this Agreement a provision requiring the
Sublicensee to keep and maintain records of Sales made pursuant to such
sublicense and to grant access to such records by EMORY's independent public
accountant. If such independent public accountant's report shows any
underpayment of royalties by CYBERKINETICS, its Affiliates or Sublicensees,
within thirty (30) days after CYBERKINETICS' receipt of such report,
CYBERKINETICS shall remit or shall cause its Sublicensees to remit to EMORY:

                  (i) the amount of such underpayment; and

                  (ii) if such underpayment exceeds * * * of the total royalties
owed for the fiscal year then being reviewed, the reasonably necessary fees and
expenses of such independent public accountant performing the audit. Otherwise,
EMORY's accountant's fees and expenses shall be borne by EMORY. Any overpayment
of royalties shall be fully creditable against future royalties payable in any
subsequent royalty periods.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       8
<PAGE>

      4.3. Confidentiality of Records. All information subject to review under
this Article 4 shall be confidential. Except where otherwise provided by law,
EMORY and its accountant shall retain all such information in confidence.

                               ARTICLE 5. PAYMENTS

      5.1. Payment Due Dates. Royalties, sublicense fees and other payments
payable to EMORY as a result of activities occurring during the period covered
by each royalty report provided for under Article 4 of this Agreement shall be
due and payable within fifteen (15) days of the date such royalty report is due.
Payments of royalties in whole or in part may be made in advance of such due
date. Any payment in excess of one hundred thousand dollars ($100,000.00) shall
be made by wire transfer to an account of EMORY designated by EMORY from time to
time; provided, however, that in the event that EMORY fails to designate such
account, CYBERKINETICS or its Affiliates and Sublicensees may remit payment to
EMORY at the address applicable for the receipt of notices hereunder; providing,
further, that any notice by EMORY of such account or change in such account,
shall not be effective until fifteen (15) days after receipt thereof by
CYBERKINETICS.

      5.2. Currency Restrictions. Except as hereinafter provided in this Article
5.2, all royalties shall be paid in Dollars. If, at any time, legal restrictions
prevent the prompt remittance of part of or all royalties with respect to any
country in the Licensed Territory where Licensed Products are Sold,
CYBERKINETICS, its Affiliates or Sublicensees shall have the right and option to
make such payments by depositing the amount thereof in local currency to EMORY's
account in a bank or depository in such country.

      5.3. Interest. Royalties and other payments required to be paid by
CYBERKINETICS pursuant to this Agreement shall, if overdue, bear interest at the
lesser of (a) the maximum applicable legal rate of interest on overdue
commercial accounts or (b) a per annum rate equal of ten percent (10%) until
paid. The payment of such interest shall not foreclose EMORY from exercising any
other rights it may have because any payment is overdue.

                  ARTICLE 6. DEVELOPMENT AND MARKETING PROGRAM

      6.1. Diligence Obligations. CYBERKINETICS shall directly, or in
collaboration with Affiliates, alliances and Sublicensees, use commercially
reasonable efforts to:

                  (i) conduct research and development programs relating to the
use of Licensed Patents and Licensed Know-How;

                  (ii) promptly register Licensed Products with regulatory
authorities in the Licensed Territory; and

                  (iii) market the Licensed Products in accordance with its
business plans and objectives.

      6.2. Fulfillment; Conversion.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       9
<PAGE>

            (a) For purposes of this Agreement, "commercially reasonable
efforts" shall mean the use of reasonable efforts including, to the extent
appropriate, pursuing sublicenses or corporate alliances, consistent with those
used by comparable biotechnology companies in the United States in research and
development projects for medical devices or kits deemed to have commercial value
comparable to the Licensed Products.

            (b) CYBERKINETICS' obligations set forth in this Article 6 shall be
deemed to have been fully satisfied during the following time periods if
CYBERKINETICS accomplishes the following specified milestones:

                  (i) Prior to * * * . CYBERKINETICS causes * * * with respect
to * * * to occur prior to * * * ;

                  (ii) Prior to * * * . CYBERNETICS causes the * * * with
respect to a * * * to occur by * * *; and

                  (iii) After * * * . CYBERNETICS * * * within * * * following
the * * * for a Licensed Product.

            (c) For clarity, the diligence obligations set forth in this Article
6 are independent of the minimum annual royalties payable pursuant to Article
3.4 and the payment of such minimum annual royalties will not relieve
CYBERKINETICS of its obligations under this Article 6.

            (d) CYBERKINETICS shall provide regular reports to EMORY after
submission of its U.S. 510 (k) filing(s) for Licensed Products concerning the
status of such filing(s) until final approval thereof, including any final
decision not to comply with any FDA request.

            (e) CYBERKINETICS will notify EMORY promptly after any final
decision by CYBERKINETICS to permanently abandon development of Licensed
Products based upon any portion of the Licensed Technology.

            (f) In the event CYBERKINETICS fails to meet any diligence
requirement set forth herein, EMORY shall have the option in its sole discretion
to (i) terminate the Agreement within the entire Licensed Territory or any
portion of the Licensed Territory for such application or indication, (ii)
convert the license granted in this License Agreement into a nonexclusive
license within the entire Licensed Territory or any portion of the Licensed
Territory for such indication, or (iii) terminate the Agreement within a portion
of the Licensed Territory and convert the license granted in this Agreement into
a non-exclusive license within a portion of the Licensed Territory. In order to
allow EMORY to determine to exercise any of the foregoing rights, in the event
CYBERKINETICS fails to meet any diligence requirement set forth herein,
CYBERKINETICS shall, on EMORY'S request, subject to agreement between
CYBERKINETICS and EMORY of terms and conditions of confidentiality, permit EMORY
to have access to all CYBERKINETICS' data related to CYBERKINETICS' development
efforts with respect to the Licensed Technology for the purpose of allowing
EMORY to assess the commercial potential of the Licensed Technology.

            (g) Prior to exercising any rights under this Article, EMORY shall
give CYBERKINETICS sixty (60) days' prior written notice and shall meet with
CYBERKINETICS, at

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       10
<PAGE>

CYBERKINETICS' request and expense, during such sixty (60) day period, to
discuss any disagreements about whether CYBERKINETICS has complied with the
requirements of this Article. CYBERKINETICS shall (i) within sixty (60) days of
CYBERKINETICS' receipt of written notice of such failure, provide to EMORY a
commercially reasonable plan to remedy such failure and (ii) cure such failure
in accordance with such plan within the time provided for under such plan. If
CYBERKINETICS fails to provide such a commercially reasonable plan within sixty
(60) days or does not cure such failure in accordance with such plan within the
time provided for under such plan, EMORY shall have the right in its sole
discretion to proceed with the exercise of all rights arid remedies provided for
herein.

      6.3. Progress Reports. CYBERKINETICS shall, no less frequently than once
every six (6) months until CYBERKINETICS has achieved Regulatory Approval for a
Licensed Product, provide EMORY with a written report detailing all activities
of CYBERKINETICS, its Affiliates and Sublicensees related to developing Licensed
Products and pursuing Regulatory Approval of Licensed Products to the extent
reasonably necessary for EMORY to review CYBERKINETICS' progress under Article
6.2. Such reports shall further, no less frequently than once per year,
incorporate sufficient and quantified detail on the resources allocated by
CYBERKINETICS to enable EMORY to determine that CYBERKINETICS is diligently
pursuing its research and development in accordance with its business plans and
this Agreement.

      6.4. Development Outside United States. As soon as practicable and in
accordance with CYBERKINETICS' corporate goals and its obligations under this
Agreement, CYBERKINETICS shall directly, or in collaboration with Affiliates and
Sublicensees, commence its commercially reasonable efforts:

                  (i) to obtain Regulatory Approval for a Licensed Product in
such other countries of the Licensed Territory as CYBERKINETICS or
CYBERKINETICS' Affiliates and Sublicensees deem appropriate; and

                  (ii) upon Regulatory Approval of a Licensed Product in a
particular country diligently commence efforts to market such Licensed Product
in such country.

                          ARTICLE 7. PATENT PROSECUTION

      7.1. CYBERKINETICS shall be responsible for preparing, filing,
prosecuting, maintaining and defending all Licensed Patents. CYBERKINETICS shall
provide EMORY with copies of all filings and relevant documentation and a
reasonable opportunity in advance to comment on such filings. CYBERKINETICS will
not abandon any patent application in the Licensed Patents, or make
prosecution-related decisions that would have a material impact on the nature or
scope of any claims in such patent applications, without giving EMORY a
reasonable opportunity to comment on such action or decision.

      7.2. CYBERKINETICS shall bear all costs in connection with the
preparation, filing, prosecution, maintenance and defense of the Licensed
Patents.

      7.3. In the event that CYBERKINETICS determines to abandon prosecution of,
or to

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       11
<PAGE>

cease to maintain, any Licensed Patent in any country, CYBERKINETICS shall so
notify EMORY and shall permit EMORY, in its sole discretion, at EMORY's expense,
to continue to prosecute or maintain such Licensed Patent in such jurisdiction,
and CYBERKINETICS shall cooperate with EMORY in regard thereto. If EMORY does so
prosecute, the licenses granted to CYBERKINETICS under Article 2.1 shall
terminate in such country with respect to any Licensed Patents issuing in such
country as a result of such prosecution.

      7.4. Each party shall, and shall cause its Affiliates, employees,
attorneys and agents to, cooperate fully with the other party and provide all
information and data and execute any documents reasonably required or requested
in order to allow the other party to prepare, prosecute, file, and maintain
patents and patent applications pursuant to this Article 7 for no additional
compensation.

                             ARTICLE 8. INFRINGEMENT

      8.1. Third Party Infringement. CYBERKINETICS and EMORY shall each promptly
notify the other in writing of any alleged or threatened infringement or claim
of invalidity (hereinafter "Infringement") of which they become aware of patents
included in the Licensed Patents, and the parties shall consult concerning the
action to be taken. CYBERKINETICS shall have the right, but not the obligation,
to prosecute or defend at its own expense any such Infringement. In such event,
CYBERKINETICS shall have the right, if EMORY is a legally indispensable party,
to bring such suit or action in the name of EMORY. CYBERKINETICS shall pay, on
behalf of and instead of EMORY, any order for costs that may be made against
EMORY by reason of it being joined as a party plaintiff in such proceedings by
CYBERKINETICS, provided that EMORY will not be obligated to reimburse
CYBERKINETICS for any costs so paid by CYBERKINETICS. CYBERKINETICS shall have
sole control of any such suit or action and all negotiations for its settlement
or compromise; provided, however, that CYBERKINETICS shall not settle or
compromise any such suit or action or enter into any consent order for the
settlement or compromise thereof that adversely affects any rights of EMORY
hereunder without the prior written consent of EMORY, not to be unreasonably
withheld.

      If, within sixty (60) days after CYBERKINETICS first becomes aware of any
Infringement of the Licensed Patents, CYBERKINETICS fails to cause such
Infringement to terminate or to bring a suit or action to compel termination,
EMORY shall have the right, but not the obligation, to bring such suit or action
to compel termination at the sole expense of EMORY. In such event, EMORY shall
have the right, if CYBERKINETICS is a legally indispensable party, to bring such
suit or action in the name of CYBERKINETICS. EMORY shall hold pay, on behalf of
and instead of CYBERKINETICS, any order for costs that may be made against
CYBERKINETICS by reason of it being joined as a party plaintiff in such
proceedings by EMORY, provided that CYBERKINETICS will not be obligated to
reimburse EMORY for any costs so paid by EMORY. EMORY shall have sole control of
any such suit or action and all negotiations for its settlement or compromise;
provided, however, that EMORY shall not settle or compromise any such suit or
action or enter into any consent order for the settlement or compromise thereof
that adversely affects any rights of CYBERKINETICS hereunder without the prior
written consent of CYBERKINETICS, not to be unreasonably withheld.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       12
<PAGE>

      8.2. Allocation of Recovery. Any recovery or damages derived from an
action under this Article 8 shall be used (i) first to reimburse the initiating
party for all legal expenses incurred by it relating to the suit and (ii) second
to reimburse the non-initiating party for all legal expenses incurred by it
relating to the suit, with any remaining recovery allocated between the parties
as follows:

            (a) To the extent the remaining amount is attributed to sales of
such infringing products, CYBERKINETICS shall receive an amount equal to such
amount less the royalties that would have been payable on such sales pursuant to
this Agreement had such sales been made by CYBERKINETICS, which royalty amount
shall be paid to EMORY.

            (b) To the extent the remaining amount is attributed to lost
royalties owed to EMORY under subparagraph (a) as a result of the infringement,
EMORY shall receive an amount equal to the royalties payable to EMORY under this
Agreement multiplied by any multiple of damages awarded in such action.

            (c) Any remaining recovery amount not attributed to sales of such
infringing products shall be divided with sixty-seven percent (67%) of such
remaining amount allocated to the party initiating such proceedings and
thirty-three percent (33%) of such remaining amount allocated to the
non-initiating party.

      8.3. Offset by CYBERKINETICS. CYBERKINETICS shall not offset its
out-of-pocket expenses incurred in regard to any such legal proceedings which
CYBERKINETICS initiates or carries on against any royalty payments or other
payments owed to EMORY except in the case of an action initiated independently
by a third party to invalidate any claims of the Licensed Patents, such as
through a reexamination. If such action occurs, CYBERKINETICS may suspend
royalty payments payable to EMORY until the action is concluded, at which time
CYBERKINETICS will make such suspended royalty payments to EMORY based upon the
Valid Claims then existing with respect to the Licensed Patents.

      8.4. EMORY's Right to Pursue Third Party Infringers If CYBERKINETICS shall
fail, within sixty (60) days after receiving notice from EMORY of a potential
infringement, or providing EMORY with notice of such infringement, to either (a)
terminate such infringement or (b) institute an action to prevent continuation
thereof and, thereafter to prosecute such action diligently, or if CYBERKINETICS
notifies EMORY that it does not plan to terminate the infringement or institute
such action, then EMORY shall have the right to do so at its own expense.
CYBERKINETICS shall cooperate with EMORY in such effort including being joined
as a party to such action if necessary. EMORY shall be entitled to retain all
damages or costs awarded to EMORY in such action.

             ARTICLE 9. EXCLUSION OF WARRANTIES AND INDEMNIFICATION

      9.1. Warranties of EMORY.

            (a) EMORY represents and warrants that, to the best of its
knowledge:

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       13
<PAGE>

                  (i) EMORY has disclosed to CYBERKINETICS all potential patent
rights in the control of third parties known to EMORY which may be needed to
commercialize the Licensed Patents, provided that for purposes of this
representation and warranty, "EMORY" shall mean the Inventor and any employees
of EMORY who work in the technology transfer area, and CYBERKINETICS
acknowledges that EMORY has not undertaken any investigation with respect to the
potential patent rights of any third party; and

                  (ii) Appendix A is a complete list of all patents and patent
applications included in the Licensed Patents as of the date hereof. EMORY will
from time to time during the term of this Agreement, promptly provide
CYBERKINETICS with, upon request, with an updated version of Appendix A.

                  (iii) EMORY is not aware of any patent infringement or notice
of any pending claim of infringement in respect of the Licensed Patents.

            (b) EMORY further represents and warrants that it is the exclusive
owner of all rights, title and interests in the patents and patent applications
identified in Appendix A as of the date hereof, subject to the rights of the
U.S. Government.

      9.2. Warranties of Each Party. Each party hereto represents to the other
that it is free to enter into this Agreement and to carry out all of the
provisions hereof, including, in the case of EMORY, its grant to CYBERKINETICS
of the license described in Article 2.1.

      9.3. Merchantability and Exclusion of Warranties. CYBERKINETICS possesses
the necessary expertise and skill in the technical areas pertaining to the
Licensed Patents, Licensed Products and Licensed Know-How to make, and has made,
its own evaluation of the capabilities, safety, utility and commercial
application of the Licensed Patents, Licensed Products and Licensed Know-How.
ACCORDINGLY, EXCEPT AS SET FORTH IN ARTICLE 9.1 AND 9.2, EMORY DOES NOT MAKE ANY
REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE LICENSED PATENTS,
LICENSED KNOW-HOW OR LICENSED PRODUCTS AND EXPRESSLY DISCLAIMS ANY WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND ANY OTHER IMPLIED
WARRANTIES WITH RESPECT TO THE CAPABILITIES, SAFETY, UTILITY, OR COMMERCIAL
APPLICATION OF THE LICENSED PATENTS, LICENSED KNOW-HOW OR LICENSED PRODUCTS.

      9.4. Indemnification by CYBERKINETICS. CYBERKINETICS shall defend,
indemnify, and hold harmless the EMORY Indemnitees, from and against any and all
claims, demands, losses, liabilities, expense, or damage (including
investigative costs, court costs and reasonable attorneys' fees) the EMORY
Indemnitees may suffer, pay, or incur as a result of claims, demands or actions
against any of the EMORY Indemnitees arising or alleged to arise by reason of,
or in connection with, any and all personal injury (including death) and
property damage caused or contributed to, in whole or in part, by CYBERKINETICS'
or CYBERKINETICS' Affiliates, contractors, agents, or Sublicensees' manufacture,
testing, design, use, Sale, or labeling of any Licensed Products. CYBERKINETICS'
obligations under this Article shall survive the expiration

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       14
<PAGE>

or termination of this Agreement for any reason.

      9.5. Insurance. Without limiting CYBERKINETICS' indemnity obligations
under Article 9.4, CYBERKINETICS shall, prior to any clinical trial or Sale of
any Licensed Product, cause to be in force, an "occurrence based type" or
"claims made type" (with reasonable tail coverage) liability insurance policy
which:

            (a) insures Indemnitees for all claims, damages, and actions
mentioned in Article 9 of this Agreement; and

            (b) includes a contractual endorsement providing coverage for all
liability which may be incurred by Indemnitees in connection with this
Agreement; and

            (c) requires the insurance carrier to provide EMORY with no less
than thirty (30) days' written notice of any change in the terms or coverage of
the policy or its cancellation; and

            (d) provides Indemnitees a comprehensive general/product liability
coverage in an amount no less than * * * per occurrence for bodily injury and
* * * per occurrence for property damage, subject to a reasonable aggregate
amount; and

            (e) in the event that CYBERKINETICS, its Affiliates or Sublicensees
decide to go to market with a Licensed Product it shall, to the extent available
at commercially reasonable rates arrange (prior to the Sale of any Licensed
Product) and shall continue for the term of this Agreement and for a period of
* * * years thereafter an insurance policy or policies of product liability
which provide Licensee, its affiliates or Sublicensees with coverage for injury
or damage arising to users of Licensed Products in an amount no less than * * *
per claim, subject to annual aggregate of * * *; and

            (f) CYBERKINETICS shall provide EMORY with a copy of any such
insurance policy prior to the commencement of clinical trials or the first Sale
of any Licensed Product and on each renewal and/or replacement of the policy
together with a copy of any schedule and evidence of payment of the premium.
Company will also advise EMORY with written notice within 30 days of any
material change in the terms or coverage of the policy or its cancellation.

            (g) EMORY may periodically review the adequacy of the minimum limits
of liability insurance specified in this Article 9.5. EMORY reserves the right
to require CYBERKINETICS to adjust the liability insurance coverage above within
reason and without significantly increasing CYBERKINETICS' annual insurance
premiums.

      9.6. Occurrence Based Coverage Not Available. If CYBERKINETICS is unable
to obtain "occurrence based type" liability insurance, CYBERKINETICS shall
procure "claims made type" liability coverage to be effective prior to any
clinical trial or Sale of any Licensed Products, and throughout the term of this
Agreement and "tail coverage", extending at least ten (10) years after
termination of this Agreement. CYBERKINETICS shall notify EMORY prior to its
first clinical trial or commercial Sale of any Licensed Product, of all
insurance coverage and

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       15
<PAGE>

other assets available to CYBERKINETICS to meet CYBERKINETICS' obligations under
Article 9 of this Agreement.

      9.7. Notice of Claims: Indemnification Procedures.

            (a) CYBERKINETICS shall promptly notify EMORY of any claims
involving any Indemnitees for which indemnification is or may be provided in
Article 9.4 and shall advise EMORY of the policy amounts that might be needed to
defend and pay any such claims.

            (b) An Indemnitee, which intends to claim indemnification under this
Article shall promptly notify the other party (the "Indemnitor") in writing of
any matter in respect of which the Indemnitee or any of its employees or agents
intend to claim such indemnification. The Indemnitee shall permit, and shall
cause its employees and agents to permit, the Indemnitor, at its discretion, to
settle any such matter and agrees to the complete control of such defense or
settlement by the Indemnitor; provided, however, that such settlement does not
adversely affect the Indemnitee's rights hereunder or impose any obligations on
the Indemnitee in addition to those set forth herein in order for it to exercise
such rights and that the Indemnitee makes no statement or undertakes any action
that may prejudice the ability of the Indemnitor to settle any such claim. No
such matter shall be settled without the prior written consent of the Indemnitor
and the Indemnitor shall not be responsible for any legal fees or other costs
incurred other than as provided herein. The Indemnitee, its employees and agents
shall cooperate fully with the Indemnitor and its legal representatives in the
investigation and defense of any matter covered by the applicable
indemnification. The Indemnitee shall have the right, but not the obligation, to
be represented by counsel of its own selection and at its expense.

                           ARTICLE 10. CONFIDENTIALITY

      10.1. Treatment of Confidential Information. Except as otherwise provided
hereunder, during the term of this Agreement and for a period of * * *
thereafter:

                  (i) CYBERKINETICS and its Affiliates and Sublicensees shall
retain in confidence and use only for purposes of this Agreement, any written
information and data supplied by EMORY to CYBERKINETICS under this Agreement and
marked as proprietary;

                  (ii) EMORY shall retain in confidence and use only for
purposes of this Agreement any written information and data supplied by
CYBERKINETICS or on behalf of CYBERKINETICS to EMORY under this Agreement and
marked as proprietary.

      For purposes of this Agreement, all such information and data which, a
party is obligated to retain in confidence shall be called "Information".

      10.2 Right to Disclose. To the extent that it is reasonably necessary to
fulfill its obligations or exercise its rights under this Agreement, or any
rights which survive termination or expiration hereof, each party may disclose
the other Party's Information to its Affiliates, Sublicensees, consultants,
outside contractors, governmental regulatory authorities and clinical.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       16
<PAGE>

investigators and in the case of CYBERKINETICS, its collaborators and potential
investors, on the condition that such entities or persons agree:

                  (i) to keep such Information confidential for at least the
same time periods and to the same extent as the disclaiming party is required to
keep the Information confidential;

                  (ii) to use such Information only for such purposes as the
disclosing party is authorized to use the Information under this Agreement;

                  (iii) not to use EMORY's name for any commercial purpose
without the prior written consent of EMORY.

      Each party, its Affiliates and Sublicensees may disclose the other party's
Information to the government or other regulatory authorities to the extent that
such disclosure is necessary for the prosecution and enforcement of patents
included within the Licensed Patents, or authorizations to conduct clinical
trials or commercially market Licensed Products, provided that such party is
entitled to engage in such activities under this Agreement or is legally
required to make such disclosures.

      10.3. Release from Restrictions. The obligation not to disclose the other
party's Information shall not apply to any part of such Information that:

                  (i) is or becomes disclosed in a patent or patent application,
published or otherwise part of the public domain, other than by unauthorized
acts of the receiving party or its Affiliates or Sublicensees in contravention
of this Agreement;

                  (ii) is disclosed to the receiving party or its Affiliates or
Sublicensees by a third party provided that such third party was not obligated
to the other party to keep such information confidential; or

                  (iii) prior to disclosure under this Agreement, was already in
the possession of the receiving party, its Affiliates or Sublicensees, provided
that such Information was not obtained directly or indirectly from the other
party under this Agreement with an obligation to keep such information
confidential;

                  (iv) the receiving party is able to demonstrate results from
research and development by the receiving party or its Affiliates or
Sublicensees independent of disclosures from the other party, provided that the
persons developing such information have not had exposure to the Information
received from the disclosing party;

                  (v) is required by law to be disclosed by the receiving party,
provided that the receiving party shall notify the other party immediately upon
learning of such requirement in order to give the other party reasonable
opportunity to oppose such requirement; or

                  (vi) the disclosing party agrees in writing may be disclosed.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       17
<PAGE>

                        ARTICLE 11. TERM AND TERMINATION

      11.1. Term. Unless sooner terminated as otherwise provided in this
Agreement, the term of this Agreement shall commence on the Effective Date and
shall continue in full force and effect, until * * *.

      11.2. Termination. EMORY shall have the right to terminate this Agreement
upon the occurrence of any one or more of the following events and provided that
EMORY has given CYBERKINETICS the notice required in Article 11.3 and
CYBERKINETICS has failed to cure the breach described in such notice:

            (a) failure of CYBERKINETICS to make any payment required pursuant
to this Agreement when due;

            (b) failure of CYBERKINETICS to render reports to EMORY as required
by this Agreement;

            (c) the institution of any proceeding by CYBERKINETICS under any
bankruptcy, insolvency, or moratorium law;

            (d) any assignment by CYBERKINETICS of substantially all of its
assets for the benefit of its creditors;

            (e) placement of CYBERKINETICS' assets in the hands of a trustee or
a receiver unless the receivership or trust is dissolved within thirty (30) days
thereafter and provided that in the case of in involuntary bankruptcy
proceeding, which is contested by CYBERKINETICS, such termination shall not
become effective until the bankruptcy court of jurisdiction has entered an order
upholding the petition;

            (f) a formal decision reduced to writing and delivered to EMORY by
CYBERKINETICS or CYBERKINETICS' assignee of all of CYBERKINETICS' rights under
this Agreement to quit the business of commercializing the Licensed Patents and
Licensed Know-How or developing or selling Licensed Products; or

            (g) the breach by CYBERKINETICS of any other material term of this
Agreement.

      11.3. Exercise. Subject to Article 15.11, EMORY may exercise its right of
termination by giving CYBERKINETICS, its trustees, receivers or assigns, thirty
(30) days' (or such other extended period agreed in writing by the parties)
prior written notice of EMORY's election to terminate. Such notice shall include
the basis for such termination. Upon the expiration of such period, this
Agreement shall automatically terminate unless CYBERKINETICS has cured the
breach where such breach is capable of being remedied within such period or
extended period as applicable. Such notice and termination shall not prejudice
EMORY's right to receive royalties up to the point of termination or other sums
due to EMORY hereunder and shall not prejudice any cause of action or claim of
EMORY accrued or to accrue on account of any breach or default by

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       18
<PAGE>

CYBERKINETICS.

      11.4. Failure to Enforce. The failure of EMORY, at any time, or for any
period of time, to enforce any of the provisions of this Agreement, shall not be
construed as a waiver of such provisions or as a waiver of the right of EMORY
thereafter to enforce each and every such provision of this Agreement.

      11.5. Termination by CYBERKINETICS. CYBERKINETICS shall have the right to
terminate this Agreement upon the occurrence of either of the following events:

            (a) the breach of a material term of this Agreement by EMORY;

            (b) if the Sale of Licensed Products requires approval by any
government agency, and after diligent pursuit of such approval, including but
not limited to: performing all reasonable tests or analyses as prescribed by
such agency regulations; submitting all relevant data to such agency; and
pursuing reasonable available administrative procedures and appeal processes
permitted by such agency and applicable law, CYBERKINETICS reasonably determines
it is unable to obtain approval for the Sale of Licensed Products or reasonably
determines such approval would, in CYBERKINETICS' sole judgment, be too
restrictive to justify continued development of a Licensed Product,
CYBERKINETICS may notify EMORY in writing of the final denial of approval to
Sell Licensed Products and CYBERKINETICS' desire to terminate this Agreement or
parts hereof related to specific Licensed Technology from which such Licensed
Products that are denied Regulatory Approval have been developed; or

            (c) upon CYBERKINETICS' convenience, upon ninety (90) days' written
notice to EMORY, provided that no such termination shall relieve CYBERKINETICS
of its obligation under Articles 3.1, 3.2, 3.3, 3.4, 3.5 and 3.6. with respect
to any milestone achieved and other payments made prior to the effective date of
such termination.

      11.6. Exercise. CYBERKINETICS may exercise its right of termination
pursuant to Article 11.5(a), by giving EMORY thirty (30) days' prior written
notice of CYBERKINETICS' election to terminate. The notice shall include the
basis for such termination. Upon the expiration of such period, this Agreement
shall automatically terminate unless EMORY has cured the breach. Such notice of
termination shall not prejudice any cause of action or claim of CYBERKINETICS
accrued or to accrue on account of any breach or default by EMORY.

      CYBERKINETICS may exercise its right of termination pursuant to Article
11.5 (b) as a result of the failure to obtain governmental approval to sell
Licensed Products by providing EMORY with a formal written request for such
termination enclosing evidence of the final denial of governmental approval.

      CYBERKINETICS may exercise its right of termination pursuant to Article
11.5 (c) by providing EMORY with written notice of such termination.

      11.7. Effect. In the event this Agreement is terminated because of
CYBERKINETICS' default, CYBERKINETICS shall return, or at EMORY's direction
destroy, all data, writings and other documents and tangible materials,
containing EMORY's Information and supplied to

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       19
<PAGE>

CYBERKINETICS by EMORY.

      Where the default for which this Agreement is terminated is set forth
under Articles 11.2(c) through (f) inclusive, subject to agreement between
CYBERKINETICS and EMORY of terms and conditions of confidentiality,
CYBERKINETICS shall provide EMORY access to CYBERKINETICS' product files
pertaining to the Licensed Products and design dossiers as well as data
generated by CYBERKINETICS' contractors and agents in the course of
CYBERKINETICS' efforts to develop Licensed Products or obtain governmental
approval for the Sale of Licensed Products to permit EMORY to assess the
commercial potential of the Licensed Technology. CYBERKINETICS agrees to
negotiate in good faith with EMORY and/or any potential licensee of the Licensed
Technology with respect to a license or sale of information, data and research
results then owned or controlled by CYBERKINETICS, including, but not limited
to, toxicity, efficacy and market research, to the extent such information, data
and research results are pertinent to the Licensed Technology. In such event,
CYBERKINETICS shall also grant EMORY and any replacement licensee of the
Licensed Technology the right to cross reference any regulatory filings (e.g.
510 (k), Registrations) made by CYBERKINETICS or its Affiliates with the FDA or
any corresponding foreign regulatory agency, in exchange for which EMORY or such
replacement licensee will reimburse CYBERKINETICS, on terms and at a rate to be
negotiated in advance in good faith by the parties involved, based on all
reasonable and documented direct and indirect, out-of-pocket costs incurred by
CYBERKINETICS in pursuing such regulatory approvals. CYBERKINETICS shall
cooperate (but shall not be required to incur any expense) with any such third
parties in pursuing governmental approval to sell any product covered by any
patent application or issued patent (which was formerly a Licensed Patent
licensed b1 EMORY to such third party.

                             ARTICLE 12. ASSIGNMENT

      CYBERKINETICS may grant, transfer, convey, or otherwise assign any or all
of its rights and obligations under this Agreement in conjunction with the
transfer of all, or substantially all, of the business interests of
CYBERKINETICS to which this Agreement relates including for the purposes of
corporate re-organization. EMORY's written consent, which shall not be
unreasonably withheld, shall be required prior to any other assignment of
CYBERKINETICS' rights or obligations under this Agreement.

                             ARTICLE 13. BANKRUPTCY

      In the event that CYBERKINETICS, for any reasons, plans the institution of
any proceeding under any bankruptcy, insolvency, or moratorium law of any
countries, CYBERKINETICS shall notify EMORY of its plan at least One Hundred and
Twenty (120) days prior to the official filing of such bankruptcy, insolvency,
or moratorium with government or legal authorities. In the event that this
Agreement or CYBERKINETICS' license to the Licensed Technology is transferred,
sold, novated or otherwise provided to a third party (the "Transferee") as part
of a bankruptcy or insolvency settlement under the ruling of a court of
competent jurisdiction, the obligations to pay royalties and other payments to
EMORY shall be borne by such Transferee.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       20
<PAGE>

                              ARTICLE 14. PUBLICITY

      Neither party shall use the name of the other, nor of any employee of such
party, in any publicity, marketing efforts, news release or any other commercial
activities without the prior written approval of an authorized representative of
the other party. Notwithstanding the foregoing, either party may disclose the
terms of this Agreement and the parties' relationship as required by law.

                            ARTICLE 15. MISCELLANEOUS

      15.1. Arbitration. Any disputes under this Agreement, shall be resolved
through arbitration conducted under the auspices of the American Arbitration
Association pursuant to that organization's rules for commercial arbitration and
shall have the right to enforce any such arbitral award. Any hearings shall be
held in Atlanta, Georgia. Both parties agree to be bound by any arbitral award
without prejudice to any other rights at law.

      15.2. Export Controls. CYBERKINETICS acknowledges that EMORY is subject to
United States laws and regulations controlling the export of technical data,
biological materials, chemical compositions and other commodities and that
EMORY's obligations under this Agreement are contingent upon compliance with
applicable United States export laws and regulations. The transfer of technical
data, biological materials, chemical compositions and commodities may require a
license from the cognizant agency of the United States government or written
assurances by CYBERKINETICS that CYBERKINETICS shall not export data or
commodities to certain foreign countries without the prior approval of certain
United States agencies. EMORY neither represents that an export license shall
not be required nor that, if required, such export license shall be issued.

      15.3. Legal Compliance. CYBERKINETICS shall use reasonable commercial
efforts to comply with all laws and regulations relating to its manufacture,
use, Sale, labeling or distribution of Licensed Products and shall not knowingly
take any action that would cause EMORY or CYBERKINETICS to violate any laws or
regulations.

      15.4. Independent Contractor. CYBERKINETICS' relationship to EMORY shall
be that of a licensee only. CYBERKINETICS shall not be the agent of EMORY and
shall have no authority to act for, or on behalf of, EMORY in any matter.
Persons retained by CYBERKINETICS as employees or agents shall not, by reason
thereof, be deemed to be employees or agents of EMORY.

      15.5. Patent Marking. CYBERKINETICS shall mark Licensed Products Sold in
the United States with United States patent numbers in accordance with
applicable U.S. laws as in effect from time to time. Products manufactured or
Sold in other countries shall be marked in compliance with the intellectual
property laws in force in such foreign countries.

      15.6. Place of Execution. This Agreement and any subsequent modifications
or amendments hereto shall be deemed to have been executed in the State of
Georgia. This

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       21
<PAGE>

Agreement shall not become effective or binding upon EMORY until signed by its
Assistant Vice President and Director of the Office of Technology Transfer in
the State of Georgia.

      15.7. Governing Law. This Agreement and all amendments, modifications,
alterations, or supplements hereto, and the rights of the parties hereunder,
shall be construed under and governed by the laws of the State of Georgia and
the United States of America. Unless otherwise resolved under the provisions of
Article 15.1, only courts in the State of Georgia shall have jurisdiction to
hear and decide any controversy or claim between the parties arising under or
relating to this Agreement.

      15.8. Entire Agreement. This Agreement constitutes the entire agreement
between EMORY and CYBERKINETICS with respect to the subject matter hereof and
shall not be modified, amended or terminated, except as herein provided or
except by another agreement in writing executed by the parties hereto.

      15.9. Survival. Articles 9, 10, 11, 14, and 15 shall survive termination
of this Agreement for any reason. Article 11.7 shall survive termination
pursuant to Article 11.2.

      15.10. Severability. All rights and restrictions contained herein maybe
exercised and shall be applicable and binding only to the extent that they do
not violate any applicable laws and are intended to be limited to the extent
necessary so that they will not render this Agreement illegal, invalid or
unenforceable. If any provision or portion of any provision of this Agreement,
not essential to the commercial purpose of this Agreement, shall be held to be
illegal, invalid or unenforceable by a court of competent jurisdiction, it is
the intention of the parties that the remaining provisions or portions thereof
shall constitute their agreement with respect to the subject matter hereof, and
all such remaining provisions, or portions thereof, shall remain in full force
and effect. To the extent legally permissible, any illegal, invalid or
unenforceable provision of this Agreement shall be replaced by a valid
provision, which shall implement the commercial purpose of the illegal, invalid,
or unenforceable provision. In the event that any provision essential to the
commercial purpose of this Agreement is held to be illegal, invalid or
unenforceable and cannot be replaced by a valid provision which will implement
the commercial purpose of this Agreement, this Agreement and the rights granted
herein shall terminate provided, however, that it is replaced forthwith by a
legally enforceable substitute agreement that maintains the contractual
relationship between the parties as contemplated herein including specifically,
the rights and privileges granted to CYBERKINETICS in respect of the Licensed
Technology.

      15.11. Force Majeure. Any delays in, or failure of performance of any
party to this Agreement, shall not constitute a default hereunder, or give rise
to any claim for damages, if and to the extent caused by occurrences beyond the
control of the party affected, including, but not limited to, acts of God,
strikes or other concerted acts of workmen, civil disturbances, fires, floods,
explosions, riots, war, rebellion, sabotage, acts of governmental authority or
failure of governmental authority to issue licenses or approvals which may be
required.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       22
<PAGE>

                               ARTICLE 16. NOTICES

      All notices, statements, and reports required to be given by one party to
the other shall be in writing and shall be deemed to have been given (i) upon
electronic confirmation of delivery, if sent by facsimile to the recipient below
followed by a copy which shall be sent by overnight delivery to the same
recipient, or (ii) upon delivery in person, or (iii) upon the expiration of five
(5) days after deposit in a lawful mail depository in the country of residence
of the party giving the notice, registered or certified postage prepaid, and
addressed as follows:

To EMORY:                    Director, Office of Technology Transfer
                             Emory University
                             2009 Ridgewood Drive
                             Atlanta, Georgia 30322

Notices related to EMORY's equity position in CYBERKINETICS, which include, but
are not limited to, stock, stock options, voting rights, etc. should be sent to:

                             Emory University
                             Office of Vice President for Finance & Treasurer
                             312 Administration Building
                             Atlanta, GA 30322

To CYBERKINETICS :           President
                             Cyberkinetics, Inc.
                             109 Hazard Avenue
                             Providence, RI 02906

With a copy to:              Ropes & Gray
                             One International Place
                             Boston, MA 02110
                             Attn: Geoffrey B. Davis, Esq.

Either party hereto may change the address to which notices to such party are to
be sent by giving notice to the other party at the address and in the manner
provided above. Any notice may be given, in addition to the manner set forth
above, by courier, facsimile or email, provided that the party giving such
notice obtains acknowledgement by courier, facsimile or email that such notice
has been received by the party to be notified. Notice made in this manner shall
be deemed to have been given when such acknowledgement has been transmitted.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       23
<PAGE>

      IN WITNESS WHEREOF, EMORY and CYBERKINETICS have caused this Agreement to
be signed by their duly authorized representatives, as of the Effective Date.

EMORY UNIVERSITY:                             CYBERKINETICS, INC.:

By: _______________________________________   By:_______________________________

Name: Mary L. Severson, Ph.D., J.D.           Name:_____________________________

Title: Assistant Vice President & Director,   Title:____________________________
       Office of Technology Transfer

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       24
<PAGE>

                                   Appendix A
                                Licensed Patents

U.S. Patent No. * * * for "* * *" Issued * * *.

***   Information redacted pursuant to a confidential treatment request. An
      unredacted version of this exhibit has been filed separately with the
      Commission.

                                       25

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00075-of-00352.parquet"}]]